The current guidelines for sweat chloride analysis identify the procedures for sweat collection, but not for chloride assay, which is usually performed by methods originally not aimed at the low concentrations of chloride found in sweat. To overcome this limitation, we set up, characterized, and adopted an original inductively coupled plasma mass spectrometry (ICP-MS) method for sweat chloride determination, which was designed for its easy use in a clinical laboratory. The method was linear in the range 8.5E−3 to 272.0E−3 mM, precision exhibited a relative standard deviation < 6%, and accuracy was in the range 99.7–103.8%. Limit of blank, limit of detection, and limit of quantitation were 2.1 mM, 3.2 mM, and 7.0 mM, respectively, which correspond to real concentrations injected into the mass spectrometer of 3.9E−3 mM for LOD and 8.5E−3 mM for LOQ. At first, the method was assessed on 50 healthy volunteers who exhibited a mean chloride concentration of 15.7 mM (25–75th percentile 10.1–19.3 mM, range 2.8–37.4 mM); then, it was used to investigate two patients with suspected cystic fibrosis, who exhibited sweat chloride values of 65.6 mM and 81.2 mM, respectively. Moreover, the method was cross-validated by assaying 50 samples with chloride concentration values in the range of 10–131 mM, by both ICP-MS and coulometric titration, which is the technology officially used in Tuscany for cystic fibrosis newborn screening. The reference analytical performances and the low cost of ICP-MS, accompanied by the advantageous cost of a single sweat chloride assay, make this technology the best candidate to provide a top reference method for the quantification of chloride in sweat. The method that we propose was optimized and validated for sweat samples ≥ 75 mg, which is the minimum amount requested by the international protocols. However, the method sensitivity and, in addition, the possibility to reduce the sample dilution factor, make possible the quantification of chloride even in samples weighting < 75 mg that are discarded according to the current guidelines. In general, ICP-MS is highly cost-effective, and the operating costs of the clinical laboratory could greatly benefit from its high versatility, which allows performing different assays, usually conducted by several machines, by just one instrument. For instance, one of these assays could be the quantification of metal elements in biological fluids that are usually quantified individually by atomic absorption and that can be assessed simultaneously by ICP-MS multi-elemental analysis.
Marvelli, A. (2022). A NEW CONFIRMATORY ASSAY FOR THE DIAGNOSIS OF CYSTIC FIBROSIS: DETERMINATION OF CHLORIDE ION BY INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY (ICP-MS) [10.25434/marvelli-antonella_phd2022].
A NEW CONFIRMATORY ASSAY FOR THE DIAGNOSIS OF CYSTIC FIBROSIS: DETERMINATION OF CHLORIDE ION BY INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY (ICP-MS)
marvelli, antonellaWriting – Review & Editing
2022-01-01
Abstract
The current guidelines for sweat chloride analysis identify the procedures for sweat collection, but not for chloride assay, which is usually performed by methods originally not aimed at the low concentrations of chloride found in sweat. To overcome this limitation, we set up, characterized, and adopted an original inductively coupled plasma mass spectrometry (ICP-MS) method for sweat chloride determination, which was designed for its easy use in a clinical laboratory. The method was linear in the range 8.5E−3 to 272.0E−3 mM, precision exhibited a relative standard deviation < 6%, and accuracy was in the range 99.7–103.8%. Limit of blank, limit of detection, and limit of quantitation were 2.1 mM, 3.2 mM, and 7.0 mM, respectively, which correspond to real concentrations injected into the mass spectrometer of 3.9E−3 mM for LOD and 8.5E−3 mM for LOQ. At first, the method was assessed on 50 healthy volunteers who exhibited a mean chloride concentration of 15.7 mM (25–75th percentile 10.1–19.3 mM, range 2.8–37.4 mM); then, it was used to investigate two patients with suspected cystic fibrosis, who exhibited sweat chloride values of 65.6 mM and 81.2 mM, respectively. Moreover, the method was cross-validated by assaying 50 samples with chloride concentration values in the range of 10–131 mM, by both ICP-MS and coulometric titration, which is the technology officially used in Tuscany for cystic fibrosis newborn screening. The reference analytical performances and the low cost of ICP-MS, accompanied by the advantageous cost of a single sweat chloride assay, make this technology the best candidate to provide a top reference method for the quantification of chloride in sweat. The method that we propose was optimized and validated for sweat samples ≥ 75 mg, which is the minimum amount requested by the international protocols. However, the method sensitivity and, in addition, the possibility to reduce the sample dilution factor, make possible the quantification of chloride even in samples weighting < 75 mg that are discarded according to the current guidelines. In general, ICP-MS is highly cost-effective, and the operating costs of the clinical laboratory could greatly benefit from its high versatility, which allows performing different assays, usually conducted by several machines, by just one instrument. For instance, one of these assays could be the quantification of metal elements in biological fluids that are usually quantified individually by atomic absorption and that can be assessed simultaneously by ICP-MS multi-elemental analysis.File | Dimensione | Formato | |
---|---|---|---|
phd_unisi_086641.pdf
accesso aperto
Licenza:
Creative commons
Dimensione
1.5 MB
Formato
Adobe PDF
|
1.5 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1223214